Company intelligence / Profile preview

Bioxytol

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Bioxytol is developing and scaling up precision fermentation processes to produce new-generation sweeteners such as erythritol and isomaltulose. The company has received environmental approval to begin operations at its new facility in Arévalo, Ávila, Spain. It aims to offer both proprietary products and contract precision fermentation services with capacities ranging from pilot scale to industrial scale. The company’s projects are supported by European regional development funds. No clinical results apply.

Therapeutic areas: Other
Modalities: Not applicable
Industry: Non-Drug Biotech

Drug pipeline

3 assets

erythritol

Commercial

Indications: Diabetes, Weight management

2 more assets in the full pipeline.

Request access →

Partnerships

European Regional Development FundICE Castilla y LeónJunta de Castilla y León

Beyond the preview

Go deeper on Bioxytol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioxytol.

Explore the full profile